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a b s t r a c t
This study was performed to present the outcomes of trigeminal neuropathy management
with the application of neurolytic block of sphenopalatine ganglion. This type of procedure is
used in cases where pain is not well controlled with medical treatment. Twenty patients
were treated with sphenopalatine ganglion neurolysis after their response to pharmacolog-
ical management was not satisfactory. Signiﬁcant pain relief was experienced by all but one
patient and they were able to reduce or stop their pain medication. The time of pain relief
was between a few months and 9 years during the study period. Number of procedures
implemented varied as some of the patients have been under the care of our Pain Clinic for as
long as 18 years, satisﬁed with this type of management and willing to have the procedure
repeated if necessary. It appears that neurolytic block of sphenopalatine ganglion is effective
enough and may be an option worth further consideration in battling the pain associated
with trigeminal neuropathy.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
Available online at www.sciencedirect.com
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Due to its complex pathophysiology, the facial pain is a clinical
challenge. One of the most common causes of unilateral facial
pain is trigeminal neuralgia (TN). In some rare cases the
clinical picture of TN change and progress to trigeminal
neuropathy, which is characterized by constant pain accom-
panied by sensory disturbances, with only episodes of typical,
neuralgiform pain. The cause of neuropathy may be an* Corresponding author at: Pain Clinic: Department of Anesthesiology a
Czerniakowska 231, 00-416 Warszawa, Poland. Tel.: +48 22 58 41 220; 
E-mail address: lmilewski@post.pl (M. Malec-Milewska).
http://dx.doi.org/10.1016/j.pjnns.2015.08.010
0028-3843/# 2015 Polish Neurological Society. Published by Elsevier Sextreme duration of TN and the destruction of peripheral
rami of the trigeminal nerve related to neurodestructive
procedures or tumors and trauma.
It should not be confused with trigeminal neuralgia, where
episodes of shooting pain prevail, with no sensory or motor
deﬁcits between them. Although the pain is usually predomi-
nant in the clinical picture, its constant character and sensory
deﬁcits that appear as the condition progresses – serve to
differentiate between the two. It should also be noted that a
damage to the rami of trigeminal nerve may be caused bynd Intensive Care, Medical Center for Postgraduate Education, Ul.
fax: +48 22 58 41 342.
p. z o.o. All rights reserved.
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Therefore, a thorough clinical evaluation is mandatory in all
cases with facial numbness before symptomatic management
is employed.
As pharmacological management is moderately effective in
trigeminal neuropathy, substantial number of patients will not
be satisﬁed with pharmacotherapy or develop some signiﬁcant
side effects. In these cases the invasive procedures are
mandated. In our center we use the neurolytic block of
sphenopalatine ganglion (SPG). This procedure had been
performed in our center since 1990 and neurolytic agent used
is 65% ethanol. There were attempts to replace it with
radiofrequency thermocoagulation (RT), but it was abandoned
due to the worse outcomes. In every case of trigeminal
neuropathy treated with RT of SPG, the alcohol neurolysis was
later performed, as improvement achieved with RT was not
satisfactory.
Trigeminal neuropathy is the most common indication for
neurolytic block of SPG in our center. We also use this
procedure in Horton migraine and tumor-related facial pain in
the area of trigeminal nerve innervation. It was used with
success in typical trigeminal neuralgia (TN) in the past, but
was replaced by RT of Gasserian ganglion more than 10 years
ago, as the latter proved to be much more effective in TN. It is a
safe procedure, which – unlike neurolytic blocks of peripheral
branches of TN – does not carry a risk of sensory deﬁcits.
Sphenopalatine ganglion (SPG), or pterygo-palatine gangli-
on (PPG) and termination of its function in pathogenesis and
treatment of facial pain has been an issue of interest for more
than a 100 years, since in 1908 Sluder described and performed
its block for the ﬁrst time [2]. He had been using SPG blocks in
patients with unilateral facial pain, located at the bridge of the
nose, radiating to periorbital area, zygomatic process, mastoid
process and occipital area. This pain was to be accompanied byFig. 1 – Sphenopalatine gautonomic symptoms (running nose, lacrimation, blood-shot
eyes) and was eventually named Sluder's neuralgia. Recent
research has conﬁrmed the importance of SPG in pathophysi-
ology of many types of facial pain and headaches, as well as
stroke and cerebral vasospasm [3]. In spite of a 100 years of
history, there is very limited number of papers reporting the
long-term outcomes of its neurolytic blocks.
1.1. Sphenopalatine ganglion anatomy
SPG consists of a large number of neurons that form the
triangular structure of approximately 5 mm. It is located on the
outside of the cranium, in the pterygopalatine fossa (PPF).
Pterygopalatine fossa contains SPG, maxillary artery with
some of its branches, venous plexus and maxillary nerve.
SPG is of mixed character: sensory, parasympathetic, and
sympathetic. Its sensory root is provided by the sphenopala-
tine nerves from maxillary nerve. They contain dendrites of
the neurons located in trigeminal ganglion (hence the
beneﬁcial effect of SPG block in TN). Sympathetic root is
formed by the efferent (postganglionic) ﬁbers provided by deep
petrosal nerve (a target of neurolytic block in trigeminal
neuropathy). Parasympathetic root is derived from facial nerve
through the greater petrosal nerve. It is formed by dendrites of
the neurons located in the upper salivary nucleus (blocking
parasympathetic ﬁbers of SPG is indicated in trigeminal
autonomic cephalalgias, like cluster headache) [4]. SPG
anatomy is presented in Fig. 1.
1.2. SPG blocks
SPG block is usually performed with the use of local
anesthetics (cocaine, lidocaine, bupivacaine) and steroids.
Neurolytic block is achieved with either chemical (ethanol oranglion anatomy [4].
Table 1 – Patient characteristics and symptom description. M – male; F – female. NRS – pain severity expressed in Numeric
Rating Scale (description in the text). V1, V2, V3 – first, second and third branch of trigeminal nerve.
No. Sex/
age
Pain
distribution
Duration of
symptoms before
SPG neurolysis
NRS
continuous
NRS
paroxysmal
Buccal
numbness
Previous interventions/
cause of neuropathy
1 M/45 V1,V2,V3 7 years 5 8 Yes Microvascular decompression
 2; V2 nerve blocks (alcohol)
2 M/56 V1,V2,V3 10 years 8 10 Yes Microvascular decompression
3 F/75 V1,V2, V3 17 years 4 9 Yes V2 nerve alcohol neurolysis
4 F/71 V2, V3 6 years 3 10 Yes None/time (6 years)
5 F/53 V2, V3 3 years 3 7 Yes Dental procedure followed by alcohol
neurolysis of V2
6 F/76 V1, V2 17 years 3 8 Yes None/time
7 M/69 V2 4 years 3 7 Yes Alcohol V2 neurolysis
8 F/56 V1, V2, V3 20 years 5 9 No None/time (20 years)
9 M/79 V2, V3 20 years 5 8 No None/time (20 years)
10 M/71 V2, V3 8 years 5 9 Yes Alcohol V2 neurolysis
11 F/52 V1, V2, V3 6 years 4 10 Yes Alcohol V2 neurolysis
12 F/65 V1, V2 13 years 3 8 No None/time (13 years)
13 M/52 V1, V2 10 years 4 8 Yes None/time (10 years)
14 F/72 V1, V2 16 years 3 9 Yes None/time (16 years)
15 M/66 V1, V2 4 years 7 9 Yes Alcohol V2 neurolysis
16 F/59 V1, V2, V3 4 years 4 8 Yes Trauma to temp-mandib joint,
alcohol V2 neurolysis
17 F/37 V2, V3 7 years 3 10 Yes Congenital polyneuropathy.
Temp-mandib joint dysfunction
18 F/64 V2, V3 7 years 3 8 Yes Temp-mandib joint dysfunction
19 F/69 V2, V3 10 years 3 8 Yes None/time (10 years)
20 F/74 V2, V3 10 years 2 9 No None/time (10 years)
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differ signiﬁcantly considering their complexity. The least
invasive approach is via nasal cavity. It is an easy technique,
used for blocks performed with local anesthetics and rarely for
neurolytic blocks [5].
Second and more complicated option is an access via
greater palatine foramen. The foramen is located at the level of
the third molar tooth. Dental 1208 needle is then introduced
through the mouth and greater palatine foramen and
advanced approx. 2.5 cm superiorly and slightly posteriorly.
There is no data on the use of this technique for neurodes-
tructive procedures.
The third and most challenging technique is the zygomatic
access, which is used for ﬂuoroscopically – guided neurolytic
block of SPG in our center.
2. Materials and methods
20 patients (7 males and 13 females) were treated with
neurolytic block of SPG for trigeminal neuropathy from 2004
until 2015. Their age was 42–79 years at the time of ﬁrst block.
Table 1 shows the data regarding duration of symptoms, pain
intensity and most likely causes of neuropathy. Pain intensity
was assessed using 11-point Numeric Rating Scale (NRS),
where 0 means no pain and 11 – worst pain imaginable. The
procedure was proposed to patients when pharmacologic
therapy failed to provide sufﬁcient pain control. All technical
aspects of the procedure, as well as potential risk and beneﬁts
were thoroughly explained before informed consent was
obtained. Coagulopathy, psychiatric disorders, opioid addic-
tion, local infection at the site of needle entry and lack ofpatient's consent were contraindications. The block was
considered successful if resulted in cessation of constant pain
and reduction or cessation of paroxysmal pain both immedi-
ately after the procedure and at the follow-up visit after 14
days.
In our center we implement the zygomatic approach. It is
performed as an outpatient procedure, with the use of C-arm
ﬂuoroscopic guidance. On the day of procedure patients use a
mouthwash with potassium permanganate, as the needle may
pass through the upper recess of the oral cavity. The patient is
positioned in supine position, with the C-arm around his/her
head. The head is then rotated until the mandibular rami and
both perygo-palatine fossae are superimposed on each other.
The view of pterygo-palatine fossa then reﬂects the shape of
an upside-down vase.
25 gauge spinal needle is introduced approx. 1 cm below the
zygomatic arch and approx. 1 cm anterior of the coronoid
process of mandible, advancing it slightly superior, medial and
posterior, toward the PPF. Block technique and crucial
anatomy points are shown in Fig. 2. In AP view the needle is
superimposed on the maxillary sinus and the injected contrast
is seen as a point over the view of maxillary sinus. AP and
lateral views of accurate needle positioning as conﬁrmed by
contrast injection is shown in Figs. 3 and 4, respectively. After
needle position is conﬁrmed, the neurolytic agent (2 ml of 65%
ethanol with lidocaine) is injected. Due to complexity of the
procedure it should be performed under ﬂuoroscopic guid-
ance, preferably by pain specialists who are experienced in
invasive pain management. Inappropriate needle placement
may result in a number of complications, most serious of them
being the ulceration of cornea if the needle is placed too deep
(inferior orbital wall) and facial nerve paralysis if the needle is
Fig. 2 – Zygomatic approach used to block SPG.
Fig. 3 – Properly positioned needle as confirmed by contrast
injection: A–P view.
Fig. 4 – Lateral view of the needle and contrast injected in
PPF.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 3 8 9 – 3 9 4392placed too shallow and neurolytic agent spreads toward the
alar foramen. Inadvertent puncture of the maxillary artery in
PPF may result in formation of hematoma, which may take up
to 3 weeks to resolve. Infraorbital spread of the neurolytic
agent may also effect in diplopia, which resolves spontane-
ously within a few days.
It does happen occasionally to postpone the procedure after
a few unsuccessful attempts to place the needle in correct
position. It is usually due to the abundance of vessels present
in PPF. SPG block with local anesthetic is then performed;
neurolytic block is planned in a few weeks time, which is then
usually uncomplicated and successful.
3. Results
Sixty-eight neurolytic blocks were performed in cases de-
scribed. A success rate was very high, as only three procedures
were postponed due to inability to place the needle in correct
position under ﬂuoroscopic imaging. In all three cases the
procedure was successful with later attempt. Similarly, the
effects of the procedure were spectacular. Summary of the
management introduced is presented in Table 2. With the
neurolytic agent injected, pain relief was noted in 19 out of 20
patients. Similarly, all 19 patients conﬁrmed the improvement
brought by the block at the follow-up visit after 14 days.
Unsuccessful case was referred for surgical intervention.
Neurosurgical decompression was done, which brought some
reasonable pain relief for a period of 3 years. After that the
radiofrequency ablation of Gasserian ganglion was performed,
but no positive outcome achieved. As presented in Table 1, the
most common cause of neuropathy was peripheral nerve
damage, either due to invasive intervention (9), trauma (2) or
congenital nerve abnormality (1). In the remaining eight cases
it was impossible to identify the speciﬁc cause of neuropathy.
All these patients have suffered from TN for many years before
symptoms of neuropathic pain became evident, like constant
pain and/or sensory disturbances, some of them for as long as
20 years. Therefore in these cases the long lasting neuralgia
was considered the cause of neuropathy. All procedures were
unilateral and patients remained under the care of our Pain
Clinic for a period of time that varied from a few months to
many years. Consequently, the number of procedures
performed varied from 1 to as many as 10. Recorded duration
of pain relief was between 2 months and more than 9 years at
the time this report was being prepared. No serious
complications were noted, apart from one case of diplopia
which resolved within a few days and one episode of bruising
at the site of needle entry. All but one of our patient was
satisﬁed with the results of the procedure and – when
indicated – would be happy to have the procedure repeated if
the pain returns.
4. Discussion
Trigeminal neuropathy may present as a major therapeutic
problem in cases where typically indicated pharmacologic
therapy is ineffective. Here we present the management
implemented in 20 cases of unilateral trigeminal neuropathy
Table 2 – Summary of the management. M – male; F – female. Age: at the time of first block. Pain relief given in months, if
sustained – means sustained during the study period. NRS – pain severity expressed in numeric rating scale (description in
the text).
Sex/
age
Time under
pain clinic
care
Pain clinic medications
prior to the block
No of
neurolytic
blocks
Average pain relief
(min–max) – months
NRS after
the single
block
1 M/45 7 Carbamazepine, Baclofen 6 18.5 (12–30) and sustained 0
2 M/56 16 Amitriptyline Carbamazepine, Baclofen 8 27 (16–48) and sustained 0
3 F/75 13 Carbamazepine, Amitriptyline 3 (36–72) and sustained 0
4 F/71 6 Carbamazepine, Lamotrigine, Baclofen,
Opipramol
1 Sustained (>7 years) 0
5 F/53 1.5 Carbamazepine, Amitriptyline 1 Sustained (>18 months) 0
6 F/76 18 Carbamazepine 5 31 (12–48) and sustained (>8 years) 0
7 M/69 10 Carbamazepine, Amitriptyline, Baclofen 2 24 and sustained (>9 years) 0
8 F/56 3 Carbamazepine, Gabapentin, Mianserin 1 No improvement 5
9 M/79 5 Carbamazepine, Baclofen, Mianserin 1 Sustained (>5 years) 0
10 M/71 9 Carbamazepine, Gabapentin, Baclofen,
Amitriptyline
1 Sustained (>8 years) 0
11 F/52 4 Carbamazepine, Lamotrigine, Baclofen,
Amitriptyline
2 12, 30 and sustained 0
12 F/65 8 Carbamazepine, Baclofen, Amitriptyline 2 30 and sustained (>6 years) 0
13 M/52 11 Carbamazepine, Amitriptyline 10 25.5 (9–60), and sustained (>1 year) 0
14 F/72 8 Carbamazepine, Lamotrigine, Baclofen,
Amitriptyline
8 10 (2–24) lost to follow-up
2 years after the last block
0
15 M/66 2 Carbamazepine, Gabapentin, Baclofen,
Mianserin
2 8 and sustained (>8 months) 0
16 F/59 6 Carbamazepine, Lamotrigine, Amitriptyline 1 Sustained (>6 years) 0
17 F/37 8 Baclofen, then Venlafaxine 1 Sustained (>7 years) 0
18 F/64 4 Carbamazepine, Lamotrigine, Baclofen,
Amitriptyline
2 14 (19–9)
Referred for surgical interv.
0
19 F/69 10 Carbamazepine, Gabapentin, Baclofen,
Amitriptyline
10 13 (3–36), sustained (>2 years) 0
20 F/74 1 CArbamazepine. Lamotrigine, Baclofen,
Trazodone
1 Sustained (>6 months) 0
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 3 8 9 – 3 9 4 393caused by either previous interventions on peripheral nerves,
chronicity of trigeminal neuralgia or congenial factors.
Although analgesic block of SPG is known to provide
signiﬁcant advantages in many conditions, its neurolytic
block appears to be uncommon and more likely to be used
in malignancy-related neuropathies [5–10]. It may be due to
seriousness of the procedure or the fact that trigeminal
neuropathy appears to be underdiagnosed in modern socie-
ties. Nevertheless, current insights into facial sensory deﬁcits
are likely to change that [1]. Destruction of the trigeminal
nerve neurons – as done in Gasserian ganglion neurolysis – is
unlikely to provide long lasting improvement in patients with
neuropathy, as pathogenesis of neuropathic pain is different
from that of neuralgia. Most of our patients developed
neuropathic pain due to neurodestruction of peripheral parts
of trigeminal nerves, while long lasting neuralgia was
considered the cause of neuropathy in eight cases. Both
continuous and paroxysmal pain relief was achieved in all but
one patient and relief time varied from a few months to a few
years. It is not possible to discuss our results with regards to
other studies directly, as research reports on SPG destruction
used to treat trigeminal neuropathy are scarce. Varghese and
Koshy used nasal approach for phenol-based neurolytic block
of SPG in patients with pain related to malignant face and neck
tumors and reported some plausible results [5]. Different
technique and cause of neuropathy does not allow to compare
their ﬁndings with ours. Gasserian ganglion radiofrequencyablation is much more popular, as well as studies evaluating
the effectiveness of its alcohol destruction, but nearly all of
them describe neurolytic procedures used to treat trigeminal
neuralgia [11,12]. Bayer et al. reported on the use of radio-
frequency ablation of SPG in patients with chronic face and
head pain and found it to be sufﬁciently effective to warrant
future studies, but no cases of trigeminal neuropathy were
treated [13]. Similarly, other reports are available where SPG
radiofrequency destruction is employed for various types of
headache [14,15]. Peripheral trigeminal neuropathy, being
relatively uncommon, is much more complex and once
diagnosed – much more challenging to manage. Patients with
trigeminal neuropathy are usually managed pharmacologi-
cally, using protocols that are recommended for other
neuropathic pain syndromes. Therefore, the use of tricyclic
antidepressants, serotonin–norepinephrine reuptake inhibi-
tors and gabapentinoids is common. Unfortunately their
effectiveness in trigeminal neuropathy is not spectacular,
hence the doses used are usually signiﬁcant and side effects
are likely [16]. Alternative treatments, resulting in reduction of
pain medication could be of great value. Recent guidelines on
interventional pain management indicate that only inconclu-
sive recommendation can be given for application of techni-
ques of brain stimulation for facial neuropathic pain, while
indication for neurodestructive procedures is given with
regards to medically refractory cases of trigeminal neuralgia
only [17].
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management of trigeminal neuropathy (including neuropathies
resulting from malignant lesions of head and neck) and (much
less frequently) cluster headache. It is also employed in atypical
facial pain, although this indication is scarce. It has been
performed in our center for more than 25 years and approxi-
mately 100 patients were treated with at least one block. Of so
many attempted procedures, complete failure to perform the
block occurred in three cases only, due to major vascular
malformation noted in PPF. All of them were treatment-
resistant trigeminal neuralgia cases. The number of complica-
tions was also negligible and none required speciﬁc medical
intervention. It appears that percutaneous alcohol neurolysis of
sphenopalatine ganglion using zygomatic approach appears to
be safe and effective in the management of trigeminal
neuropathy.
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